Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Great Rebate Debate: Why Do They Exist?

Executive Summary

A Senate hearing on drug pricing and the supply chain inevitably focused on the role of rebates. Committee Chairman Lamar Alexander offered a simple-sounding solution: get rid of them. That’s easier said than done, of course, but it did trigger some interesting discussion from different trade sectors.


Related Content

Drug Pricing: US Senate Hearings Conclude With No Clear View On Legislation
Mehta Analysis: Race To Harness Data Will Revolutionize PBM System
Drug Pricing ‘Opacity,’ Degrees Of Transparency Debated By National Academies Panel





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts